ClinicalTrials.gg
RecruitingNCT07258979Updated Dec 2, 2025

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

A Phase 1/2 interventional study of YL201 and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 20 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-02.

Primary conditionNasopharyngeal CarcinomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nasopharyngeal Carcinoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Nasopharyngeal Carcinoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing toripalimab in Nasopharyngeal Carcinoma — 22 open to participants now, 26 under way, 7 of them phase 3. toripalimab · Nasopharyngeal Carcinoma.

Planned enrollment
8th of 36
202 · median 67
Started
2025
with 7 others
Phase 1/2
4 of 36
3 open now
Primary completion
2028-02
later than 16 of 25 live
Registered
32nd of 36
by date

Among the 36 studies testing toripalimab in Nasopharyngeal Carcinoma, this one is the 8th largest by planned enrollment, is one of 8 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 16 of the 25 other live ones, and was the 32nd registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

22 of the 36 studies testing toripalimab in Nasopharyngeal Carcinoma are open now, in 2 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing toripalimab in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.

03

Conditions studied

  • Recurrent or Metastatic Nasopharyngeal Carcinoma

Browse trials for

Keywords

  • YL201
  • recurrent or metastatic nasopharyngeal carcinoma
  • Toripalimab
04

In context

Nasopharyngeal Carcinoma Reclassified

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

This study's planned enrollment of 202 is above the median of 100 across 557 interventional studies indexed under Nasopharyngeal Carcinoma.

Browse Nasopharyngeal Carcinoma studies →

Lead sponsor

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 23 studies on the registry; 18 are open to participants now.

Compared within Nasopharyngeal Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign a written form (ICF).
  2. Aged ≥18 years and ≤75 years, male or female.
  3. performance status score of 0 or 1.
  4. ≥ 3 months.
  5. Disease and treatment history:

    1. or cytologically confirmed recurrent or nasopharyngeal carcinoma that is not amenable to curative treatment.
    2. Patients with newly diagnosed advanced nasopharyngeal carcinoma, categorized as Stage IV according to the 9th Edition of the American Joint Committee on Cancer (AJCC) Staging System; or those with recurrent nasopharyngeal carcinoma deemed unsuitable for local treatment
    3. Metastatic or recurrent patients who are systemic treatment naïve.
  6. At least one according to v1.1.
  7. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. History of other malignant tumors within 5 years prior to the first dose of study drug. Subjects who have been cured of other tumors by local therapy, such as basal cell carcinoma, squamous cell carcinoma of skin, bladder cancer in situ, cervical carcinoma in situ, or breast cancer in situ, are not excluded.
  2. Patients with brainstem , , spinal cord metastases, or spinal cord compression.
  3. Patients with severe, uncontrolled cardiovascular disease.
  4. Patients with concomitant pulmonary disease resulting in clinically severe impairment of respiratory function.
  5. History of interstitial lung disease (ILD) or non-infectious pneumonitis requiring therapy, OR current ILD or non-infectious pneumonitis.
  6. Prior treatment with a B7-H3 targeted therapy (including antibodies, antibody-drug conjugates [ADCs], CAR-T cells, and other agents), or with a topoisomerase I inhibitor or an ADC containing a topoisomerase I inhibitor payload.
  7. Prior treatment with a PD-(L)1 inhibitor (including antibodies, antibody-drug conjugates [ADCs], CAR-T cells, and other agents).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
202 participants (estimated)

Study arms

  • Experimental
    Dose Exploration (Part 1)

    To evaluate the safety and efficacy of YL201 combined with Toripalimab in subjects with recurrent or metastatic nasopharyngeal carcinoma

    Drug: YL201 · Drug: Toripalimab

  • Experimental
    Dose Exploration (Part 2)

    To evaluate the safety and efficacy of YL201 combined with Toripalimab with/without Cisplatin in subjects with recurrent or metastatic nasopharyngeal carcinoma.

    Drug: YL201 · Drug: Toripalimab · Drug: Cisplatin

Interventions

  • DrugYL201

    YL201 will be administered as an IV infusion

  • Toripalimab will be administered as an IV infusion

  • Cisplatin will be administered as an IV infusion

07

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-limiting toxicities (DLTs)

    Time frame: Approximately within 36 months

  2. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: Approximately within 36 months

  3. Progression-Free Survival (PFS) as assessed by RECIST v1.1

    Time frame: Approximately within 36 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Approximately within 36 months

  2. Disease Control Rate (DCR)

    Time frame: Approximately within 36 months

  3. Time to Response (TTR)

    Time frame: Approximately within 36 months

  4. Duration of Response (DoR)

    Time frame: Approximately within 36 months

  5. Overall survival(OS)

    Time frame: Approximately within 36 months

  6. Incidence of anti-drug antibodies (ADA) to YL201 (and to Toripalimab, if necessary)

    Time frame: Approximately within 36 months

  7. Characterize the PK parameter AUC of YL201 and its metabolites, if applicable

    Time frame: Approximately within 36 months

  8. Characterize the PK parameter Cmax of YL201 and its metabolites, if applicable

    Time frame: Approximately within 36 months

  9. Characterize the PK parameter Ctrough of YL201 and its metabolites, if applicable

    Time frame: Approximately within 36 months

  10. Characterize the PK parameter t1/2 of YL201 and its metabolites, if applicable

    Time frame: Approximately within 36 months

08

Study locations

1 of 20 sites recruiting
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Not yet recruiting
    • Study Coordinator · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Zhangzhou Municiple Hospital of Fujian Province
    Zhangzhou, Fujian, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Dongguan People's Hospital
    Dongguan, Guangdong, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
    Recruiting
    • Study Coordinator · Contact
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Jiangmen Central Hospital
    Jiangmen, Guangdong, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Yuebei People's Hospital
    Shaoguan, Guangdong, China
    Not yet recruiting
    • Study Coordinator · Contact
  • The Second Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi, China
    Not yet recruiting
    • Study Coordinator · Contact
  • The First Affiliated Hospital of Hainan Medical University
    Haikou, Hainan, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Hunan Cancer Hospital
    Changsha, Hunan, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
    Not yet recruiting
    • Study Coordinator · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Sichuan Cancer Hospital
    Chengdu, Sichuan, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Yunnan Cancer Hospital
    Kunming, Yunnan, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Study Coordinator · Contact
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Feb 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 2, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Feb 2028
CompletionEst.
May 2028
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07258979
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Nov 5, 2025
Primary completion
Feb 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Dec 2, 2025

Study contacts

MediLink Study Team
Contact
clinicaltrials@medilinkthera.com
+86 512 62858368

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tambotatug pelitecan · Toripalimab

Start the discussion